Journal of Gynecologic Oncology

Papers
(The TQCC of Journal of Gynecologic Oncology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Circ_0075960 targets the miR-202-5p/CTNND1 axis to promote the growth and migration of endometrial carcinoma cells via regulating Wnt/β-catenin signaling activity154
Evaluation of secondary cytoreduction surgery in platinum-resistant ovarian cancer patients within three-line recurrent: a multicenter, randomized controlled study50
Nomogram for predicting pathology upstaging in patients with EIN: is sentinel lymph node assessment useful in these patients?45
Missing a chance to prevent: disparities in completion of genetic evaluation in high-risk patients with endometrial cancer41
Increased cardiovascular disease risk among adolescent and young adult survivors of cervical cancer40
Laparoscopic radical hysterectomy without uterine manipulator or vaginal tube use37
The efficacy of the levonorgestrel intrauterine system versus oral megestrol acetate in treating atypical endometrial hyperplasia: a superior randomized controlled trial35
Practice guideline for management of endometrial cancer in Thailand: a Thai Gynecologic Cancer Society consensus statement30
Prognostic influence of an early time to chemotherapy following primary cytoreductive surgery for advanced epithelial ovarian cancer29
Para-aortic lymph node dissection with or without nerve-sparing in gynecological malignancies28
Developing standardized informed consent for hysterectomy and vulva cancer surgery27
Optimal number of neoadjuvant chemotherapy cycles prior to interval debulking surgery in advanced epithelial ovarian cancer: a systematic review and meta-analysis of progression-free survival and over25
Impact of adjuvant chemotherapy on the overall survival of patients with resectable bulky small cell neuroendocrine cervical cancer: a JSGO-JSOG joint study25
Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey24
Pregnancy complications and outcomes in patients with early endometrial cancer or atypical hyperplasia after fertility-sparing treatment23
Fertility-sparing treatment outcomes using immune checkpoint inhibitors in endometrial cancer patients with Lynch syndrome23
Salvage hysterectomy for persistent residual cervical cancer: assessment of prognostic factors22
Comparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, 21
Elucidation of genomic origin of synchronous endometrial and ovarian cancer (SEO) by genomic and microsatellite analysis21
Functions, interactions and prognostic role of POLE: a bioinformatics analysis19
Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy19
The 7th Biennial Meeting of the Asian Society of Gynecologic Oncology, November 25th to 27th, 202118
Current peritonectomy practice during debulking surgery in patients with newly diagnosed advanced ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 4004)17
Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review17
Evaluation of the role of liver metastasectomy in the treatment of stage IV endometrial cancer17
Genomic landscape of advanced endometrial cancer analyzed by targeted next-generation sequencing and the cancer genome atlas (TCGA) dataset17
Efficacy of edoxaban for the treatment of gynecological cancer-associated venous thromboembolism: analysis of Japanese real-world data17
Prognostic significance of heterologous component in carcinosarcoma of the gynecologic organs: a systematic review and meta-analysis16
A step towards the ambition of precision oncology in recurrent ovarian cancer16
East Asian Gynecologic Oncology Trial Group (EAGOT): founding history and future perspective16
Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer16
Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan16
Risk of CIN2+ in women aged >60 years with abnormal cervical cancer screening: a multicenter retrospective cohort study from the Thai Gynecologic Cancer Society research group16
Enrichment for the POLE mutated against p53 wild subtype using clinicopathologic factors and cyclin B1 immunohistochemistry in endometrial cancer15
A multimodal intervention program to improve sexual health and self-perceived quality of life in patients treated for cervical cancer: a randomized prospective study (PROVIDENCE trial)14
RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma14
Supragastric lesser sac: an insidious site for surgical exploration during the debulking surgery in advanced ovarian cancer14
Efficacy and toxicity of PARP inhibitor in elderly patients with homologous recombination-deficient newly diagnosed advanced ovarian cancer: the role of dose modification13
Clinical evaluation of a droplet digital PCR assay for detecting POLE mutations and molecular classification of endometrial cancer13
Fertility and prognosis assessment between bleomycin/etoposide/cisplatin and paclitaxel/carboplatin chemotherapy regimens in the conservative treatment of malignant ovarian germ cell tumors: a multice13
Cervical screening among Chinese females in the era of HPV vaccination: a population-based survey on screening uptake and regular screening following an 18-year organized screening program13
Diagnostic accuracy and prognostic factors of uterine serous carcinoma in Japanese women: a multi-center study13
Therapeutic effects of surgical debulking of metastatic lymph nodes in cervical cancer IIICr: a trial protocol for a phase III, multicenter, randomized controlled study (KGOG1047/DEBULK trial)13
Development of a prognostic prediction support system for cervical intraepithelial neoplasia using artificial intelligence-based diagnosis12
Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis12
Cost-effectiveness of atezolizumab plus chemotherapy for advanced/recurrent endometrial cancer12
Intra- and postoperative complications associated with diaphragmatic surgery for advanced ovarian cancer12
Emergency craniotomy: a life-saving procedure as part of multi-modal therapy of GTN12
Significance of histology and nodal status on the survival of women with early-stage cervical cancer: validation of the 2018 FIGO cervical cancer staging system12
Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis12
Transabdominal cardiophrenic lymph node dissection for cytoreductive surgery in advanced ovarian cancer11
Humanized patient-derived xenograft mouse model bearing ovarian clear cell carcinoma11
Clinical implications of the superficial uterine vein pattern for the dissection of the anterior layer of the vesicouterine ligament in radical hysterectomy11
Preoperative serum microRNAs as potential prognostic biomarkers in ovarian clear cell carcinoma11
Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy11
Implementation rate and related factors of confirmatory tests following an abnormal Pap smear: a nationwide study from the National Health Insurance11
Differentiation of uterine fibroids and sarcomas by MRI and serum LDH levels: a multicenter study of the KAMOGAWA study11
Cost-effectiveness analysis of hospital treatment volume and survival outcomes in endometrial cancer in Japan11
Adjuvant pelvic radiation versus observation in intermediate-risk early-stage cervical cancer patients following primary radical surgery: a propensity score-adjusted analysis11
Adjuvant carboplatin and paclitaxel with “sandwich” method radiotherapy for stage III or IV endometrial cancer: long-term follow-up at a single-institution10
HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma10
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a “real-life setting”10
Navigating the future of fertility preservation: advanced predictive strategies for treatment outcomes of endometrial atypical hyperplasia and carcinoma10
Development and validation of a prognostic model based on metabolic risk score to predict overall survival of endometrial cancer in Chinese patients10
Evaluation of clinical usefulness of HPV-16 and HPV-18 genotyping for cervical cancer screening10
A prospective comparison of the diagnostic accuracies of ultrasound and magnetic resonance imaging in preoperative staging of endometrial cancer10
Identification of the prognostic immune subtype in copy-number high endometrial cancer10
Incidence and risk factors for the development of cerebral metastasis in cervical cancer patients10
The necessity of adjuvant surgery for patients with high-risk chemorefractory or relapsed gestational choriocarcinoma with complete remission after anti-PD-1 therapy9
Evaluation of perioperative management of advanced ovarian (tubal/peritoneal) cancer patients: a survey from MITO-MaNGO Groups9
LncRNA linc01194 promotes the progress of endometrial carcinoma by up-regulating SOX2 through binding to IGF2BP19
Laparoscopy-assisted laterally extended endopelvic resection and sacrectomy (beyond laterally extended endopelvic resection) for platinum-sensitive recurrent ovarian cancer9
Evolving standards and future directions for systemic therapies in cervical cancer9
Reviewer recognition in 20249
Risk of ovarian cancer in women with pelvic inflammatory disease and homologous recombination repair gene mutations under 55: a population-based cohort study9
RAIDS atlas of significant genetic and protein biomarkers in cervical cancer9
The sealing effect of magnetic-sealing uterine manipulator in isolated uterus from patients with early-stage cervical cancer: a pre-clinical study9
Prognostic value of complete metabolic response on 18F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer8
Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia8
The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma8
Can surgery boost the survival benefit of chemoradiotherapy in T1b1-T2a1 stage cervical cancer with lymph node metastasis? A population-based study8
A phase II trial evaluating the efficacy and safety of repeated high dose medroxyprogesterone acetate (MPA) therapy for patients with recurrent early-stage endometrial cancer or atypical endometrial h8
Protective ostomies in ovarian cancer surgery: a systematic review and meta-analysis8
Comparison of progression-free survival outcome of sentinel node biopsy without ultrastaging versus lymphadenectomy in endometrial cancer: a propensity-matched analysis8
Th2 cells infiltrating high-grade serous ovarian cancer: a feature that may account for the poor prognosis8
Alternative splicing of PSMD13 mediated by genetic variants is significantly associated with endometrial cancer risk8
Bevacizumab combined with chemotherapy could be superior to chemotherapy alone in relapsed ovarian cancer after PARPi: evidence from a multi-center propensity score-matched analysis8
Validation of HPV triage in cytology-based cervical cancer screening for ASC-US cases using Japanese data8
The SHAPE trial: is good is good enough?8
Sentinel node mapping in endometrial cancer7
Cancer-field surgery for endometrial cancer by robotic peritoneal mesometrial resection and targeted compartmental lymphadenectomy (PMMR+TCL)7
Effect of adjuvant treatment on survival in 2023 FIGO stage IIC endometrial cancer7
The pathologic and clinical outcomes of risk-reducing salpingo-oophorectomy in asymptomatic carriers of homologous recombination repair gene mutation7
CircSMAD2 accelerates endometrial cancer cell proliferation and metastasis by regulating the miR-1277-5p/MFGE8 axis7
Platinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysis7
Erratum: The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women’s cancer research organization7
Clinical practice guidelines for cervical cancer: an update of the Korean Society of Gynecologic Oncology Guidelines7
Incidence and treatment outcomes of uterine cervical cancer in Korea 1999–2018 from the national cancer registry7
The 8th Biennial Meeting of the Asian Society of Gynecologic Oncology, December 1st to 3rd, 20237
Comparison of carboplatin-based chemotherapy versus cisplatin-based chemotherapy in the treatment of malignant gonadal germ cell tumor: a systematic review and meta-analysis7
Asian Society of Gynecologic Oncology (ASGO) 2024 Annual Meeting in Bali, Indonesia7
Response to Corcept’s retraction request on manuscript of “Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study”7
Cause-specific mortality rate of ovarian cancer in the presence of competing risks of death: a nationwide population-based cohort study7
Minimally invasive radical hysterectomy and the importance of avoiding cancer cell spillage for early-stage cervical cancer: a narrative review7
Bispecific immunotherapy MEDI5752 or volrustomig and cervical cancer6
Effectiveness of craniotomy and long-term survival in 35 patients with gestational trophoblastic neoplasia with brain metastases: a clinical retrospective analysis6
Prognostic values of tumor size and location in early stage endometrial cancer patients who received radiotherapy6
TP53 variants in p53 signatures and the clonality of STICs in RRSO samples6
Impact of COVID-19 on gynecologic cancer treatment in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO)6
Comparison of the safety between cervical conization and hysterectomy for patients with cervical adenocarcinoma in situ6
Diagnostic significance and predictive efficiency of metabolic risk score for fertility-sparing treatment in patients with atypical endometrial hyperplasia and early endometrial carcinoma6
Challenges and perspectives on less invasive surgery for early-stage cervical cancer: a critical analysis of the SHAPE trial and its implications6
Clinicopathologic and protein markers distinguishing the “polymerase epsilon exonuclease” from the “copy number low” subtype of endometrial cancer6
Prevention of symptomatic pulmonary embolism for gynecologic malignancies with preoperative asymptomatic venous thromboembolism: GOTIC-VTE trial6
Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of O6
Revisiting the meaning of Trousseau sign and syndrome6
Rotational intraperitoneal pressurized aerosol chemotherapy with paclitaxel and cisplatin: pharmacokinetics, tissue concentrations, and toxicities in a pig model6
Improved bladder function in radical hysterectomy without worsening oncologic outcome: resection of the posterior layer of the vesicouterine ligament with the procedure limited to the vesical veins6
Targeting BRAF pathway in low-grade serous ovarian cancer6
Mutations in homologous recombination repair genes in patients with metastatic endometrial cancer: association with clinical characteristics and prognosis6
0.20526599884033